The Medical Device Business Journal — Medical Device News & Articles | MassDevice

As far back as the early 1960s, researchers toyed with the idea of delivering medication through contact lenses.

Johnson & Johnson Vision (NYSE:JNJ) Director of Clinica Science Dr. Brian Pall told Drug Delivery Business News that patents back then disclosed how a soft contact lens of hydrogel material could be an effective vehicle for delivering medication to the eye.

On March 2, well over half a century since the notion was floated, Johnson & Johnson announced that the FDA approved its Acuvue Theravision with Ketotifen. It’s the first drug-eluting contact lens authorized for marketing in the U.S.

Already approved in Japan and Canada, Acuvue Theravision with Ketotifen is the world’s first contact lens of its kind, according to Pall.

“[Eye drops] are just not a super-efficient way to deliver medication to a target tissue,” Pall said. “That’s what I believe is the primary reason so many people have been looking into how to develop a drug-eluting contact lens. I’m certainly proud to be part of the team that was able to finally get it across the finish line.”

Get the full story at our sister site, Drug Delivery Business News.

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Optical/Ophthalmic, Pharmaceutical, Regulatory/Compliance Tagged With: FDA, Johnson & Johnson, Johnson & Johnson Vision

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.